Aiming to test IGF2BP1’s oncogenic potential in a sympatho-adrenal neuroblastoma model, we established transgenic LSL-IGF2BP1-IRES-iRFP mice (Supplementary Fig. 9a), essentially as previously described for MYCN and Lin28b [66, 67]. The gene discussed is IGF2BP1; the disease is neuroblastoma.